BridgeMD
Evaluation of postoperative recovery when combining intravenous lidocaine with ropivacaine infiltration in laparoscopic colorectal oncologic surgery: a randomized controlled trial
EU CTIS ID: 2025-523207-29-00
What this study is testing
Evaluate the effectiveness of combining intravenous lidocaine and ropivacaine infiltration of laparoscopic trocar sites on postoperative recovery as assessed using the QOR-15 twenty-four hours after colorectal surgery.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients undergoing scheduled laparoscopic colorectal cancer surgery.
- Patients aged 18 years or older
- Highly effective method of contraception for women of childbearing age (combined hormonal contraception (estrogen and progesterone) combined with ovulation inhibition (oral, intravaginal, transdermal), hormonal contraception (progesterone only) combined with ovulation inhibition (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral fallopian tube occlusion, vasectomized partner, sexual abstinence.
- Informed consent and signed agreement
- Enrollment in a Social Security plan
You likely can't join if
- Allergy or contraindication to lidocaine or ropivacaine,
- Patients under guardianship, conservatorship, or legal protection
- Allergy or contraindication to paracetamol, nefopam, ketamine, propofol, dexamethasone, sufentanil , Celebrex or Parecoxib, , morphine derivatives, and Colorectal surgery by laparotomy
- Colorectal surgery by laparotomy
- Colorectal surgery not indicated for cancer treatment
- Chronic preoperative pain (defined as pain persisting for more than 3 months),
See the full eligibility criteria
- Patients undergoing scheduled laparoscopic colorectal cancer surgery.
- Patients aged 18 years or older
- Highly effective method of contraception for women of childbearing age (combined hormonal contraception (estrogen and progesterone) combined with ovulation inhibition (oral, intravaginal, transdermal), hormonal contraception (progesterone only) combined with ovulation inhibition (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral fallopian tube occlusion, vasectomized partner, sexual abstinence.
- Informed consent and signed agreement
- Enrollment in a Social Security plan
- Allergy or contraindication to lidocaine or ropivacaine,
- Patients under guardianship, conservatorship, or legal protection
- Allergy or contraindication to paracetamol, nefopam, ketamine, propofol, dexamethasone, sufentanil , Celebrex or Parecoxib, , morphine derivatives, and Colorectal surgery by laparotomy
- Colorectal surgery by laparotomy
- Colorectal surgery not indicated for cancer treatment
- Chronic preoperative pain (defined as pain persisting for more than 3 months),
- Preoperative use of opioids or opioid derivatives,
- Patients suffering from psychiatric disorders
- Patients for whom pain self-assessment using a self-assessment scale cannot be performed (non-communicative, non-English-speaking, etc.)
- Pregnant or breastfeeding women
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.